Results 161 to 170 of about 18,037 (235)

Implication of the Dose of Mineralocorticoid Receptor Antagonist Following Transcatheter Edge-to-Edge Mitral Valve Repair. [PDF]

JACC Asia
Imamura T, Tanaka S, Fukuda N, Ueno H, Kinugawa K, Kubo S, Yamamoto M, Izumi Y, Saji M, Asami M, Enta Y, Shirai S, Izumo M, Mizuno S, Watanabe Y, Amaki M, Kodama K, Yamaguchi J, Naganuma T, Bota H, Ohno Y, Hachinohe D, Yamawaki M, Mizutani K, Otsuka T, Hayashida K, the, OCEAN-Mitral Investigators.   +27 more
europepmc   +1 more source

A Ten Year Overview of Adrenal Vein Sampling in Croatia: Insights and Outcomes

Clinical Endocrinology, Volume 105, Issue 5, Page 533-539, November 2026.
ABSTRACT Background Adrenal vein sampling (AVS) is the gold standard for subtype differentiation in primary aldosteronism (PA), yet it remains technically demanding and resource intensive. However, data on long‐term performance, learning curves, and concordance with imaging in real‐world clinical practice are limited.
Karin Zibar Tomsic, Ana Marija Alduk, Elvira Kresic, Ivana Kraljevic, Darko Kastelan   +4 more
wiley   +1 more source

Review of Hyperkalemia Profile for Mineralocorticoid Receptor Antagonist in Patients with Chronic Kidney Disease and Type 2 Diabetes.

Cardiorenal Med
Kendrick JB, Dixon AM.
europepmc   +1 more source

Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS). [PDF]

Pragmat Obs Res
Richard EL, Stephenson JJ, Desai NR, Willey VJ, Gay A, Scott C, Folkerts K, Pessina E, Singh R, Teng CC, Oberprieler NG.   +10 more
europepmc   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9941-9954, November 2026.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo, Akira Okada, Takashi Sakamoto, Hideo Yasunaga   +3 more
wiley   +1 more source

Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

Journal of Diabetes Investigation, Volume 17, Issue 11, Page 1956-1966, November 2026.
ABSTRACT Aims Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear.
Makoto Ohara, Takemasa Omachi, Nobuaki Takehana, Tomoki Fujikawa, Naoya Osaka, Shunichiro Irie, Michishige Terasaki, Yusaku Mori, Takanori Matsui, Sho‐ichi Yamagishi   +9 more
wiley   +1 more source

Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease. [PDF]

Egypt Heart J
Pradhan A, Tripathi UC.
europepmc   +1 more source

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, Volume 17, Issue 11, Page 1904-1916, November 2026.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonist Use Among Patients With Chronic Kidney Disease Who Transitioned to Dialysis. [PDF]

Kidney Med
Tong EM, Zhou H, Pak K, Huang CW, Broder BI, Sim JJ.   +5 more
europepmc   +1 more source

Long‐term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study

Journal of Diabetes Investigation, Volume 17, Issue 11, Page 1917-1926, November 2026.
ABSTRACT Aims To investigate the long‐term renal effects of tofogliflozin, with the shortest half‐life among sodium–glucose cotransporter 2 inhibitors, in real‐world clinical practice. Materials and methods We retrospectively enrolled patients with type 2 diabetes mellitus treated at three affiliated hospitals between January 2015 and May 2024.
Natsuko Shinagawa, Hiroshi Okada, Junya Hironaka, Shinta Yamamoto, Mari Yoneda, Sayaka Kawai, Yuto Saijyo, Tomoya Katayama, Hanako Nakajima, Akio Kishi, Noriyuki Kitagawa, Naoko Nakanishi, Masahide Hamaguchi, Michiaki Fukui   +13 more
wiley   +1 more source